Ant Group’s ESG strategy aims to support 100 million SMEs by 2030
1.6.2022 06:07:00 EEST | Business Wire | Press release
Ant Group, a global technology provider, today announced its Environmental, Social and Governance (ESG) strategy as part of its latest sustainability report. The ESG strategy, which lays out Ant Group’s sustainable development objectives by 2030, will be implemented across all aspects of the Company’s operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531006112/en/
Four pillars of Ant Group’s ESG strategy and objectives by 2030 (Graphic: Business Wire)
Ant Group’s ESG strategy is focused around four pillars: Digital Inclusion, Green and Low-carbon Development, Open Ecosystem, and Technological Innovation. Each of the pillars has a corresponding sustainable development objective by 2030:
- Digital Inclusion: support 100 million small and micro-sized enterprises (SMEs) and serve communities globally
- Green and Low-carbon Development: achieve corporate carbon neutrality and support business partners and the general public to significantly reduce their carbon footprint
- Open Ecosystem: continue to provide a safe, trusted, diversified and open ecosystem to drive common development with partners
- Technological Innovation: continue to invest in core technology research and development to provide world-leading technological products and services
"We believe these are the most important pillars for Ant Group to achieve sustainable growth in a future-facing, responsible, and responsive manner,” wrote Eric Jing, Ant Group’s Chairman and CEO, in the sustainability report. ”This framework will guide Ant Group’s value creation and sustainable development in the future.”
Ant Group formulated its ESG strategy based on a comprehensive assessment of changing macro environment and policy trends, its own development strengths, and inputs from the Company’s stakeholders, including customers, users, employees, partners and governments. The ESG strategy was finalized after extensive management discussions and a detailed Board review.
After solicitating feedback from stakeholders, Ant Group defined 19 material issues for its ESG strategy, ranging from “responsible products and services,” “facilitating industry-wide carbon neutrality,” “cutting-edge technology discovery and R&D” and “transparency & risk management.”
To provide organizational support to effectively implement the ESG strategy, the Company’s Board of Directors has approved the establishment of an ESG sustainable development committee, comprised of a subset of the Board, responsible for decision-making supervision, risk management and policy making. The Company is setting up an advisory committee consisting of internal and external ESG experts to provide input and support. Ant Group has also set up an ESG sustainable development leadership team, led by the CEO and the Chief Sustainability Officer, as well as working groups for each of the 19 ESG material issues.
“Our ESG strategy originated from our own long-term needs and was not a spur-of-the-moment decision. The pursuit of sustainable development has been inherent in every step of our journey and is not designed to cater to short-term trends, but rather a necessary driver to realize our vision to be a good company that will last for at least 102 years,” added Mr. Jing. “A good company is never independently defined. We will listen to the opinions and suggestions from all parties with an open mind and welcome supervision and guidance from all of our stakeholders.”
As part of its “Technological Innovation” pillar, Ant Group has been increasing its R&D investments, which grew at an annual rate of more than 39% for three consecutive years (2018-2021), with total R&D spending in 2021 exceeding RMB 18.8 billion (approx. USD 2.77 billion). These investments enabled the Company to continuously turn technological breakthroughs into innovative, inclusive and reliable products and services to support the digital transformation of industries and better anticipate the evolving needs of an increasingly digital global economy. In 2021, MYbank, an Ant Group associate and an online SME bank, leveraged digital technology to deliver convenient, accessible and responsible collateral-free financing services to 45 million SMEs.
In February 2022, Ant Group was recognized as a Top 100 Global Innovator™ 2022 by Clarivate™. This prestigious annual list identifies global companies and institutions that contribute new ideas, solve problems and create new economic value.
Since 2017, three years after Ant Group’s establishment, the Company has steadily introduced and advanced its ESG assessment framework and published an annual sustainability report, compiled according to the Global Reporting Initiative standards. These reports, including the latest 2021 edition with the Company’s ESG strategy, can be found on Ant Group’s website (Chinese only for now, English edition will be online in the coming weeks).
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006112/en/
Contact information
Media Inquiries
Le SHEN
Shenle.sl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom